Previous 10 | Next 10 |
The FDA approves Novartis' (NYSE: NVS ) Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (defined as a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelinatio...
B.Riley FBR analyst Mayank Mamtani starts Medicinova (NASDAQ: MNOV ) at Buy. More news on: MediciNova, Inc., Read more ...
LA JOLLA, Calif., March 24, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional data from the completed SPRINT-MS Phase ...
LA JOLLA, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensiv...
LA JOLLA, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Scientific Reports has published results from the...
Preliminary data from a Phase 1 single- and multiple-ascending dose clinical trial evaluating Scholar Rock's ( SRRK +1.8% ) myostatin activation inhibitor SRK-015 in healthy volunteers showed a favorable safety profile and initial proof-of-mechanism. More news on: Scholar Rock Holding...
Gainers: Invacare (NYSE: IVC ) +69% . Reebonz Holding ( RBZ ) +38% . Arcimoto (NASDAQ: FUV ) +35% . Electrameccanica Vehicles (NASDAQ: SOLO ) +21% . CyberArk Software (NASDAQ: CYBR ) +20% . Outlook Therapeutics (NASDAQ: OTLK ) +20% . GWG Holdings (NASDAQ: GWGH ) +19% . Ma...
Clinical Trials NASH is a progressive chronic liver disease with many causal pathogenic factors. We have learnt from research that dysregulation of the glucose and lipid metabolic pathways could be associated with the development of NASH. Inflammation and activation of the apoptotic (i.e. ce...
The USPTO has issued MediciNova (NASDAQ: MNOV ) a notice of allowance for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. More news on: MediciNova, ...
LA JOLLA, Calif., Jan. 21, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. P...
News, Short Squeeze, Breakout and More Instantly...
LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MN...
LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN...
Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is p...